Atossa Therapeutics, Inc. (ATOS) income statement
ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.81−0.09 (-4.74%)
Close on Nov 18, 2026Market cap $18.06MP/E –Yield –
Atossa Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -62.7%
Financial strength
- Current ratio
- 5.69
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 478.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.67
- Dividend yield
- –
See a number that looks wrong?